Spinal Inflammatory Disease

AbbVie's Humira Was Rejected by The US FDA Advisors for Use in The Treatment
Jul 25, 2013
AbbVie's Humira (adalimumab), a rheumatoid arthritis drug, has been rejected by the US FDA advisors for use in the treatment of a spinal inflammatory disease, non-radiographic axial spondyloarthritis. The FDA's Arthritis Advisory ...

Tags: Spinal Inflammatory Disease, Medicine